Edition:
India

ANI Pharmaceuticals Inc (ANIP.OQ)

ANIP.OQ on NASDAQ Stock Exchange Global Market

66.98USD
18 Jun 2018
Change (% chg)

-- (--)
Prev Close
$66.98
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
38,021
52-wk High
$74.63
52-wk Low
$42.26

Latest Key Developments (Source: Significant Developments)

ANI Pharmaceuticals Announces Approval Of Morphine Sulfate Oral Solution
Wednesday, 18 Apr 2018 

April 18 (Reuters) - ANI Pharmaceuticals Inc ::ANI PHARMACEUTICALS ANNOUNCES APPROVAL OF MORPHINE SULFATE ORAL SOLUTION.ANI PHARMACEUTICALS INC - RECEIVED APPROVAL FROM U.S. FDA OF ITS ANDA FOR MORPHINE SULFATE ORAL SOLUTION 10MG/5ML, 20MG/5ML AND 100MG/5ML.  Full Article

Ani Pharmaceuticals Enters Five-Year $125 Mln Senior Secured Credit Facility With Citizens Bank
Friday, 29 Dec 2017 

Dec 29 (Reuters) - Ani Pharmaceuticals Inc ::ANI PHARMACEUTICALS ENTERS FIVE-YEAR $125 MILLION SENIOR SECURED CREDIT FACILITY WITH CITIZENS BANK.ANI PHARMACEUTICALS SAYS FACILITY ALSO INCLUDES A $50 MILLION SENIOR SECURED REVOLVING CREDIT FACILITY WHICH REMAINS UN-DRAWN.ANI PHARMA SAYS TERM LOAN ALSO USED TO REFINANCE EXISTING INDEBTEDNESS OF $25 MILLION.  Full Article

Ani Pharmaceuticals Acquires Four NDAs From AstraZeneca For $46.5 Mln
Friday, 29 Dec 2017 

Dec 29 (Reuters) - Ani Pharmaceuticals Inc ::ANI PHARMACEUTICALS ACQUIRES FOUR NDAS FROM ASTRAZENECA FOR $46.5 MILLION.ANI PHARMACEUTICALS INC - ACQUISITIONS WERE FUNDED THROUGH A COMBINATION OF CASH AND DEBT.ANI PHARMACEUTICALS SAYS ADDITION OF ASSETS WILL BE MATERIAL TO REVENUE AND EBITDA IN 2018.  Full Article

ANI Pharmaceuticals Q3 gaap earnings per share $0.40
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - ANI Pharmaceuticals Inc :ANI Pharmaceuticals reports record third quarter and year-to-date 2017 results and narrows full year guidance.Q3 adjusted Non-GAAP earnings per share $1.11.Q3 GAAP earnings per share $0.40.Q3 revenue $48.2 million versus I/B/E/S view $48.1 million.Q3 earnings per share view $0.99 -- Thomson Reuters I/B/E/S.ANI Pharmaceuticals Inc sees ‍for full year 2017 net revenues $181 million to $183 million​.ANI Pharmaceuticals Inc sees ‍for full year 2017 adjusted Non-GAAP diluted earnings per share $3.83 to $4.00​.Q3 earnings per share view $0.99, revenue view $48.1 million -- Thomson Reuters I/B/E/S.FY2017 earnings per share view $3.84, revenue view $182.1 million -- Thomson Reuters I/B/E/S.ANI Pharmaceuticals Inc - ‍ANI intends to request a meeting with fda in Q4 of 2017 to present its regulatory filing plan​.  Full Article

Ani Pharma acquires Inderal XL and Innopran XL
Friday, 24 Feb 2017 

Ani Pharmaceuticals Inc : Ani pharmaceuticals acquires inderal® xl and innopran xl® . Ani pharmaceuticals inc - acquisitions were funded through a combination of cash and debt . Ani pharma - has begun selling inderal xl 80mg, 120mg sustained release capsules, innopran xl 80mg, 120mg sustained release capsules under current labels . Ani pharma - will transition inderal xl and innopran xl to ani label at a future date . Ani pharmaceuticals inc - acquired inderal xl from cranford pharmaceuticals, llc and innopran xl from holmdel pharmaceuticals lp .Ani pharmaceuticals inc- acquired inderal xl from cranford pharmaceuticals, llc and innopran xlfrom holmdel pharmaceuticals lp.  Full Article

ANI Pharmaceuticals Q2 adjusted earnings per share $1.11
Thursday, 4 Aug 2016 

ANI Pharmaceuticals : Reports record second quarter results and increases full year 2016 guidance . Q2 GAAP earnings per share $0.10 . Q2 earnings per share view $0.77 -- Thomson Reuters I/B/E/S . Q2 adjusted non-GAAP earnings per share $1.11 . Q2 revenue $31.3 million versus I/B/E/S view $27.6 million . Increases full year 2016 guidance . Sees full-year 2016 revenue $119 million to $134 million . Sees full-year 2016 adjusted non-GAAP earnings per share $4.00 to $4.25 .Full-year 2016 earnings per share view $3.63, revenue view $124.2 million -- Thomson Reuters I/B/E/S.  Full Article

ANI Pharmaceuticals announces FDA approval, launch of Nilutamide tablets
Monday, 18 Jul 2016 

ANI Pharmaceuticals Inc : ANI Pharmaceuticals announces FDA approval and immediate launch of Nilutamide tablets, the first generic competitor to Nilandron® .ANI will immediately launch product.  Full Article

BRIEF-ANI Pharmaceuticals Reports Q1 GAAP Earnings Per Share $0.19

* ANI PHARMACEUTICALS REPORTS FIRST QUARTER 2018 RESULTS AND REAFFIRMS GUIDANCE